Wiki Number: W069
Diagnosis: Down Syndrome
US Patients: 1 in 1000 babies
World Patients: 5 Mil
Age Onset: Ave IQ-50
Brain Area: Also know as Trisomy 21 due to a third set of genes.
Symptoms: Ages 8-9 maximum mental development.
Progression: probability of a Down-born child increases with the age of the parents.
Causes: 3rd copy of Chromosome 21
Medications: None listed.
Therapies: Support and education
Youtube Video: Down Syndrome Journey
Amazon or Library Book:
Mental Wellness in Adults with Down Syndrome
Amazon or Library Book:
Up, Not Down Syndrome
Click the book to link or buy through Amazon.
Click the book to link or buy from Amazon.
Support Group: ndss.org; 800-221-4602
(National Down Syndrome Society)
4 CURRENT ARTICLES
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- Parkinsonism in Genetic Neurodevelopmental Disorders: A Systematic Reviewby Emma N M M von Scheibler on January 26, 2023
CONCLUSION: Parkinsonism has been reported in many GNDs. Findings from this study may provide clues for further research and improve management of patients with GNDs and/or parkinsonism.
- Case report: Ketogenic diet acutely improves cognitive function in patient with Down syndrome and Alzheimer's diseaseby Annette Bosworth on January 26, 2023
Ketogenic diets have a century-long history as a therapeutic tool to treat intractable epilepsy. Recently, a renewed interest in neuroketotherapeutics has arisen, with ketogenic diets being explored for the treatment of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease, as well as mental health conditions. Herein, we present a case report of a 47-year-old woman with Down syndrome diagnosed with Alzheimer's disease and absence seizures with accelerated cognitive...
- Identification of the potential biomarkers associated with circadian rhythms in heart failureby Qiang Sun on January 26, 2023
CONCLUSION: Our study validated that ARNTL, CRY2, BHLHE41 and NPAS2 could serve as potential biomarkers of circadian rhythm in HF. These results may provide a reference for employing novel markers or targets for the diagnosis and treatment of HF.
- Willingness to Pay for Down Syndrome Screening: A systematics Reviewby Shima Nikjoo on January 26, 2023
Background:Financial ability to pay has a unique role in the accessibility of health care services, which indicates the necessity of raising enough funds by governments. However, how much households are willing to pay (WTP) for receiving a particular service? And what factors influence their WTP? The current systematic review aimed to, firstly, review studies on the WTP for Down syndrome (DS) screening, and, secondly, to identify factors that affect WTP for DS screening. Methods:We...